文献速递肿瘤 PET/CT

68Ga-PSMA-11(HBED-CC)延迟PET/CT显像在前列腺癌诊断中的临床影响

The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer.
PubMed 文献 · J Nucl Med · 2017-01-06

该研究回顾性分析112例前列腺癌患者,比较注射后1小时早期与3小时延迟68Ga-PSMA-11 PET/CT。延迟显像中多数病灶SUVmax和对比度更高,膀胱放射性更低(尤其使用呋塞米者),并检出更多肿瘤病灶。

要点

  • 注射后3小时延迟显像中62.4%病灶SUVmax更高、65.1%对比度更高。
  • 8例(7.1%)早期不明确病灶在3小时延迟显像可明确为前列腺癌特征。
  • 使用呋塞米患者膀胱内SUV和放射性浓度更低。

核心结论

  • 注射后3小时68Ga-PSMA-11 PET/CT显示多数前列腺癌特征病灶具有更高摄取和对比度。
  • 延迟显像膀胱内放射性信号更低,尤其在使用呋塞米时。
  • 因此注射后3小时显像较1小时显像检出更多肿瘤病灶。

研究设计与样本

  • 回顾性评估2011年至2016年间112例接受早期(注射后1小时)和延迟(注射后3小时)68Ga-PSMA-11 PET/CT的前列腺癌患者。
  • 延迟扫描用于明确早期扫描中的不明确发现,或在早期扫描阴性时提高肿瘤检出概率。
  • 所有患者被要求在早期与延迟扫描之间饮水1 L,另有20例患者在延迟扫描前接受20 mg呋塞米。
  • 在69例有病理发现的患者中测量了149个肿瘤病灶的SUVmax和对比度。

主要发现

  • 注射后1小时57例患者中134个前列腺癌特征病灶清晰显示,注射后3小时68例患者中147个病灶清晰显示。
  • 43例患者无病理发现。
  • 8例(7.1%)早期扫描有1个不明确发现,在注射后3小时可明确为前列腺癌特征。
  • 4例(3.6%)仅在注射后3小时呈现1个前列腺癌特征病灶。
  • 12例(10.7%)在注射后1小时呈现12个可能前列腺癌病灶,但延迟扫描未能确认。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although PET/CT with 68Ga-PSMA-11 in the diagnosis of prostate cancer (PCa) is routinely performed at 1 h after injection, later scans may be beneficial because most lesions present with higher uptake and contrast. This evaluation aimed to investigate the clinical impact of additional late 68Ga-PSMA-11 PET/CT. Methods: Between 2011 and 2016, 112 patients with PCa who underwent early (at 1 h after injection) and late (at 3 h after injection) 68Ga-PSMA-11 PET/CT scans were retrospectively evaluated. The late scans were conducted to clarify unclear findings in early scans or to increase the probability of tumor detection in the case of negative early scans. All patients were asked to drink 1 L of water between early and late scans. In addition, 20 patients received 20 mg of furosemide before late scans. Tumor detection and radioactivity concentration within the urinary bladder were analyzed in both scans. The SUVmax and contrast of 149 tumor lesions were measured in 69 patients with pathologic findings. Results: Overall, 134 lesions characteristic for PCa in 57 patients clearly presented at 1 h after injection and 147 lesions in 68 patients at 3 h after injection. Forty-three patients showed no pathologic findings. Eight patients (7.1%) showed 1 unclear finding in early scans, which could be clarified as characteristic for PCa at 3 h after injection. Four patients (3.6%) presented with 1 lesion characteristic for PCa at 3 h after injection only. Twelve patients (10.7%) presented with 12 possible PCa lesions at 1 h after injection, which, however, could not be confirmed as PCa in late scans. Two patients presented with 1 lesion characteristic for PCa at 1 h after injection, which became invisible at 3 h after injection because of low contrast. At 3 h after injection, 62.4% of the lesions demonstrated a higher SUVmax and 65.1% a higher contrast than at 1 h after injection. Patients with furosemide presented with lower SUV and radioactivity concentration within the urinary bladder. Conclusion:68Ga-PSMA-11 PET/CT at 3 h after injection showed most lesions characteristic for PCa with a higher uptake and contrast. In addition, the radioactivity signal within the urinary bladder was lower at 3 h after injection, especially when furosemide was applied. Consequently, scans at 3 h after injection detected more tumor lesions than at 1 h after injection.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Afshar-Oromieh A, Sattler LP, Mier W, et al. The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer. J Nucl Med. 2017. PMID: 28062595. doi:10.2967/jnumed.116.183483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。